Credit Suisse Ag Chinook Therapeutics, Inc. Transaction History

Credit Suisse Ag

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$18.66 - $38.58 $329,908 - $682,094	17,680 Added 51.62%	51,931 $2 Million
Q1 2023 May 10, 2023	BUY	$21.53 - $26.8 $44,653 - $55,583	2,074 Added 6.45%	34,251 $792,000
Q4 2022 Feb 13, 2023	BUY	$18.63 - $27.35 $48,885 - $71,766	2,624 Added 8.88%	32,177 $843,000
Q3 2022 Nov 10, 2022	BUY	$17.51 - $23.37 $49,395 - $65,926	2,821 Added 10.55%	29,553 $581,000
Q2 2022 Aug 12, 2022	BUY	$12.59 - $18.8 $336,555 - $502,561	26,732 New	26,732 $467,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.